• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Niraparib increases progression-free survival in patients with ovarian cancer

byNiki WintersandDeepti Shroff Karhade
January 8, 2020
in Obstetrics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer.

2. In this phase 3 trial, patients with newly diagnosed advanced ovarian cancer who received niraparib had a significantly longer progression-free survival than those who received placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ovarian cancer has a high mortality rate worldwide and up to 85% of those treated with chemotherapy have disease recurrence. Data on bevacizumab maintenance therapy is limited. Olaparib has been associated with longer progression-free survival among patients with BRCA-mutated tumors. Niraparib, a PARP1 and PARP2 inhibitor, has been approved for maintenance therapy among patients with recurrent ovarian cancer with and without BRCA mutations. This randomized, phase 3 trial assessed the effect of niraparib in patients with newly diagnosed advanced ovarian cancer after treatment with a platinum-based chemotherapy. Participants were followed to determine progression-free survival, overall survival, and adverse events of niraparib. The median progression-free survival was higher among patients in the niraparib groups as compared to the placebo groups. In addition, the estimated 24-month survival was higher in the niraparib groups. The most common adverse effects were anemia, thrombocytopenia, and neutropenia. No deaths were reported and no difference in quality-of-life scores were found between the groups. This well-designed trial shows the effectiveness of niraparib as maintenance therapy in preventing ovarian cancer recurrence in patients after receiving chemotherapy. Further research needs to be done to determine the long-term efficacy of niraparib.

Click to read the study in NEJM

Relevant Reading: Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review

In-Depth [randomized controlled trial]: This randomized, double-blind, phase 3 trial was conducted in 20 countries between July 2016 and June 2018 with a total of 733 participants.  Participants were 18 years of age or older with newly diagnosed stage III or IV ovarian cancer that had received platinum-based chemotherapy with partial or complete response. Participants were assessed for a homologous-recombination deficiency (HRD), defined as the presence of a BRCA deleterious mutation, and considered as part of the overall population if they did not have this mutation. Participants were randomly assigned to receive oral niraparib or placebo for 36 months and followed via imaging for disease recurrence. The primary outcome was progression-free survival in those with HRD mutation and in those without the HRD mutation. The secondary outcomes were overall survival and safety. 50.9% of participants had tumors with HRD. The median progression-free survival in patients with the HRD mutation was 21.9 months with niraparib and 10.4 months with placebo (hazard ratio 0.43; 95% CI, 0.31 to 0.59; P<0.001). Overall survival was higher in these patients with an estimated 24-month survival of 91% in the niraparib group and 85% in the placebo group. In patients without the HRD mutation, median progression-free survival was 13.8 months with niraparib and 8.2 months with placebo (hazard ratio, 0.62; 95% CI, 0.50 to 0.76; P<0.001). Overall estimated 24-month survival in this group was 84% in the niraparib group and 77% in the placebo group. The most common adverse effects of niraparib were anemia (31%), thrombocytopenia (28.7%), and neutropenia (12.8%). Myelosuppression was the primary reason for discontinuation.

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Ovarian cancer screening does not reduce mortality [Classics Series]

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: homologous-recombination deficiency (HRD)niraparibovarian cancerPARP (polyadenosine diphosphate-ribose polymerase) inhibitors
Previous Post

#VisualAbstract: Obeticholic acid for the treatment of non-alcoholic steatohepatitis

Next Post

Adenotonsillectomy for obstructive sleep apnea in young children has no effect on cognition

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Obstetrics and Gynecology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

September 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Ovarian cancer screening does not reduce mortality [Classics Series]

August 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

August 10, 2022
Lower target oxygen saturation in extremely preterm infants appears safe
Oncology

Apatinib plus pegylated liposomal doxorubicin as an alternative treatment option in platinum-resistant ovarian cancer

July 11, 2022
Next Post
Quick Take: Assessment of application-driven postoperative care in the pediatric tonsillectomy population: a survey-based pilot study

Adenotonsillectomy for obstructive sleep apnea in young children has no effect on cognition

#VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

#VisualAbstract: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

Researchers validate scoring of postconcussive symptom measure to characterize duration 

Shorter time to clinic assessment linked to improved recovery time following concussion

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dual antiplatelet therapy discontinued 9 months after percutaneous coronary intervention associated with improved morbidity and mortality
  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options